June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Comparison of subjective responses to cyclosporine 0.05% versus lifitegrast 5.0% in individuals with dry eye disease
Author Affiliations & Notes
  • Elyana Vittoria Tessa Locatelli
    Ophthalmology, VA Miami Healthcare System, Miami, Florida, United States
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Kelly Acuna
    Ophthalmology, VA Miami Healthcare System, Miami, Florida, United States
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Arianna Tovar
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Jason Betz
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Anat Galor
    Ophthalmology, VA Miami Healthcare System, Miami, Florida, United States
    Ophthalmology, University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Elyana Locatelli None; Kelly Acuna None; Arianna Tovar None; Jason Betz None; Anat Galor None
  • Footnotes
    Support  Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences R&D (CSRD) I01 CX002015 (Dr. Galor), Biomedical Laboratory R&D (BLRD) Service I01 BX004893 (Dr. Galor), Rehabilitation R&D (RRD) I21 RX003883 (Dr. Galor), Department of Defense Gulf War Illness Research Program (GWIRP) W81XWH-20-1-0579 (Dr. Galor) and Vision Research Program (VRP) W81XWH-20-1-0820 (Dr. Galor), National Eye Institute U01 EY034686 (Dr. Galor), R01EY026174 (Dr. Galor) and R61EY032468 (Dr. Galor), NIH Center Core Grant P30EY014801 (institutional) and Research to Prevent Blindness Unrestricted Grant GR004596-1 (institutional).
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3952. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elyana Vittoria Tessa Locatelli, Kelly Acuna, Arianna Tovar, Jason Betz, Anat Galor; Comparison of subjective responses to cyclosporine 0.05% versus lifitegrast 5.0% in individuals with dry eye disease. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3952.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine subjective response to cyclosporine A (CsA) 0.05% versus lifitegrast 5% in individuals with dry eye disease (DED).

Methods : Retrospective review of individuals with clinically diagnosed DED treated with both CsA 0.05% and lifitegrast 5% over the course of their disease. Information collected included demographics, co-morbidities, and DED signs. Treatment preferences were noted as mild or strong for a particular medication, no preference, or unable to tolerate either medication. The primary outcome measure was patient-reported medication preference. The secondary outcome measure was an examination of individual and eye factors that related to medication preference.

Results : 64 individuals (mean age 66.73±13.17 years; 82.8% male, 71.9% White, 29.7% Hispanic) used both CsA and lifitegrast over the course of their disease. Of those, 33 preferred CsA (12.5% mildly, 39.1% strongly); 14 preferred lifitegrast (3.1% mildly, 18.8% strongly); 12 had no preference (18.8%); and 5 could not tolerate either medication (7.8%) due to side effects. No demographic characteristics, co-morbidities, or ocular surface findings correlated with medication preference.

Conclusions : In individuals who used both CsA 0.05% and lifitegrast 5% over the course of their disease, a higher frequency of individuals preferred CsA. No clinical factors correlated with medication preference.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×